Featured Research

from universities, journals, and other organizations

Don't be afraid: very old patients treated with Vitamin K antagonists, if adequately managed, benefit from anticoagulation

Date:
August 29, 2011
Source:
European Society of Cardiology
Summary:
Results of the EPICA Study (Elderly Patients followed by Italian Centers for Anticoagulation Study), were presented at the ESC Congress 2011 today. This is the largest study on very old patients anti-coagulated with vitamin K antagonists for the prevention of venous thromboembolism and, for the major part (75 percent), for the prevention of stroke because affected by atrial fibrillation.

Results of the EPICA Study (Elderly Patients followed by Italian Centres for Anticoagulation Study), were presented at the ESC Congress 2011. This is the largest study on very old patients anticoagulated with Vitamin K antagonists for the prevention of venous thromboembolism and, for the major part (75%), for the prevention of stroke because affected by atrial fibrillation.

All studied patients started the anticoagulant treatment after the age of 80 years, and the median age of studied patients was 84 years, ranging from 80 to 102 years. Fear of bleeding is the major concern for Vitamin K antagonist prescription, in particular in very old patients who carry many risk factors for bleeding. This study demonstrates a low rate of bleeding complications, notwithstanding the particularly advanced age of the patients, suggesting that age in itself should not be considered a contraindication to this treatment.

The prevalence of atrial fibrillation is strongly dependent on age and is present in nearly 10% of subjects after the age of 80 years. Given the aging of the population in western countries, the number of individuals with AF is likely to increase substantially in the next few years. Atrial fibrillation increases the risk of stroke 4 -5-fold, across all age groups, and it is estimated that the percentage of stroke attributable to atrial fibrillation rose up to 23.5% in the age group of 80 to 89 year-olds.

In the EPICA study, all patients were followed-up for anticoagulation management by specifically devoted Centres and showed a good quality of anticoagulation. Centres in this study, routinely practiced patient education, including explaining the purposes of treatment, risk of complications and information about laboratory controls.

"Actually, we know that well informed patients carry a lower risk for adverse events during anticoagulant treatment. Family members and care givers are also involved in the education programme. Due to the variable effect of oral anticoagulants that is present among the individuals and over time also for the single subject, patients receive a detailed prescription of daily dosages and the indication for the subsequent visits. The good management of anticoagulation probably explains the low bleeding risk recorded in this study," explained Dr Daniela Poli, from Thrombosis Centre AOU Careggi Firenze -Italy.

The EPICA study shows that the use of the 'old' Vitamin K antagonists is beneficial for very old people. "This is interesting especially now, because we are waiting for the 'new' oral anticoagulant drugs, that will be marketed in Europe in the next few months. No information is available at the moment for their use in very old people. In addition, it should be noted that renal failure is one of the main risk factors for bleeding and our study outlined also that the major part of very old patients have a severe or moderate renal insufficiency, that is known to get worse with age. Unlike 'old' anticoagulants, the 'new' ones have a prevalent renal route of excretion and are contraindicated in renal failure. Therefore, a large group of old patients should be carefully monitored over time to detect worsening of renal function that not infrequently happens for intercurrent illnesses, such as infection or heart failure," said Dr Poli.

This large study on very old patients on VKA treatment, showed that the rate of bleeding complications was low, suggesting that age in itself should not be considered a contraindication to treatment. An adequate management of VKA therapy with the careful monitoring of patients, in specifically trained Centres, allows very old and frail patients to benefit from VKA thromboprophylaxis.


Story Source:

The above story is based on materials provided by European Society of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

European Society of Cardiology. "Don't be afraid: very old patients treated with Vitamin K antagonists, if adequately managed, benefit from anticoagulation." ScienceDaily. ScienceDaily, 29 August 2011. <www.sciencedaily.com/releases/2011/08/110829114026.htm>.
European Society of Cardiology. (2011, August 29). Don't be afraid: very old patients treated with Vitamin K antagonists, if adequately managed, benefit from anticoagulation. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2011/08/110829114026.htm
European Society of Cardiology. "Don't be afraid: very old patients treated with Vitamin K antagonists, if adequately managed, benefit from anticoagulation." ScienceDaily. www.sciencedaily.com/releases/2011/08/110829114026.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

House Republicans Vote to Sue Obama Over Healthcare Law

House Republicans Vote to Sue Obama Over Healthcare Law

Reuters - US Online Video (July 31, 2014) The Republican-led House of Representatives votes to sue President Obama, accusing him of overstepping his executive authority in making changes to the Affordable Care Act. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
Despite Health Questions, E-Cigs Are Beneficial: Study

Despite Health Questions, E-Cigs Are Beneficial: Study

Newsy (July 31, 2014) Citing 81 previous studies, new research out of London suggests the benefits of smoking e-cigarettes instead of regular ones outweighs the risks. Video provided by Newsy
Powered by NewsLook.com
Dangerous Bacteria Kills One in Florida

Dangerous Bacteria Kills One in Florida

AP (July 31, 2014) Sarasota County, Florida health officials have issued a warning against eating raw oysters and exposing open wounds to coastal and inland waters after a dangerous bacteria killed one person and made another sick. (July 31) Video provided by AP
Powered by NewsLook.com
Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins